Bringing Gene Supplementation Therapy for PDE6A Associated Retinopathies in Clinical Practice

01.10.2016 bis 31.05.2019

The goal of the RD-CURE consortium is to develop and establish supplemental gene therapy for i) CNGA3-linked achromatopsia and ii) PDE6A-associated retinal dystrophies including first phase I/II safety and efficacy trials in human patients.
WP6 is the management project of the RD-CURE consortium and is responsible for (1) the administrative and budgetary management of the project, (2) the scientific management of the project including monitoring of project progress, lead of consortia meetings and conference calls, risk management and conflict resolution, preparation and submission of eports, (3) external communication and public relations, and (4) seeking opportunities and partnerships for future clinical trials and coordination of activities towards coordinated research activities in ocular gene therapy.